New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent ciprofloxacin 250 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg;   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent ciprofloxacin 500 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent ciprofloxacin 750 mg   excipient: colloidal silicon dioxide hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

rex medical ltd - ciprofloxacin hydrochloride 291.08mg equivalent to ciprofloxacin base 250 mg;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291.08mg equivalent to ciprofloxacin base 250 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose purified talc croscarmellose sodium macrogol 6000 magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc titanium dioxide

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

rex medical ltd - ciprofloxacin hydrochloride 582.16mg equivalent to ciprofloxacin base 500 mg;   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582.16mg equivalent to ciprofloxacin base 500 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose purified talc croscarmellose sodium macrogol 6000 magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc titanium dioxide

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

rex medical ltd - ciprofloxacin hydrochloride 873.24mg equivalent to ciprofloxacin base 750 mg;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873.24mg equivalent to ciprofloxacin base 750 mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose purified talc croscarmellose sodium macrogol 6000 magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc titanium dioxide

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - pantoprazole sodium sesquihydrate 45.12mg equivalent to pantroprazole 40.0 mg (2% manufacturing overage not included) - powder for injection - 40 mg - active: pantoprazole sodium sesquihydrate 45.12mg equivalent to pantroprazole 40.0 mg (2% manufacturing overage not included)

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 1000 [iu] equivalent to 90 µg;   - injection with diluent - 1000 iu - active: moroctocog alfa 1000 [iu] equivalent to 90 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 2000 [iu] equivalent to 180 µg;   - injection with diluent - 2000 iu - active: moroctocog alfa 2000 [iu] equivalent to 180 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 250 [iu] equivalent to 23 µg;   - injection with diluent - 250 iu - active: moroctocog alfa 250 [iu] equivalent to 23 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.